Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Rifampicin at High Dose for the Treatment of Adult Subjects With Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis

NCT04768231 is registered in ClinicalTrials.gov with Hospital Universitari Vall d'Hebron Research Institute as lead sponsor.

NCT NCT04768231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04768231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Rifampicin at High Dose for the Treatment of Adult Subjects With Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2021
Completion date
December 31, 2023
Enrollment
130 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis